Drugs / Tryptophan
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT03341286 | Nov 2017 → Jan 2019 | cancer | Faculdade de Medicina do ABC | Unknown | No outcome recorded |
| Phase 2 | NCT00000324 | Mar 1997 → Apr 2001 | cocaine dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02067975 | Aug 2014 → Dec 2019 | schizophrenia | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00202124 | Apr 2001 → Mar 2002 | Alzheimer disease | Queen's University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT04013555 Background | Jan 2020 → Aug 2024 | schizoaffective disorder, schizophrenia, schizophreniform disorder | University of Maryland, Baltimore | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tryptophan | “This is a oral supplement combination of tryptophan and thiamine called TK3 to be taken three times a day” NCT03341286 ↗ |
| Known as | TRYP | “a major metabolic product of tryptophan (TRYP).” PMID 37118058 ↗ Apr 2023 |
| Modality | Other / unclassified | “the amino acid tryptophan” NCT02067975 ↗ |
| Route | Oral | “a single oral dose of TRYP (6 g)” PMID 37118058 ↗ Apr 2023 |